Name: Oxaliplatin (NSC 266046)
Brand: Selleck Chemicals
SKU: S1224
Rating: 5 (139 reviews)

Oxaliplatin (NSC 266046) Chemical Structure

CAS No. 61825-94-3

Selleck's Oxaliplatin (NSC 266046) has been cited by 139 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Related Compound Libraries

Other DNA/RNA Synthesis Products

Download Inhibitor Catalog

DNA/RNA Synthesis Signaling Pathway Map

Biological Activity

Description

Oxaliplatin (NSC 266046, L-OHP, Eloxatin) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.

Features

This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).^[9]

Targets

DNA synthesis ^[1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)

In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. ^[1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. ^[2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Caco2	MVTGeY5kfGmxbjDBd5NigQ>?	NUjSWoltOzBxMUCwxsDPxE1?	M3XxXFE3yqCq	M3TadGROW09?	MYHhZ5RqfmG2ZYOgUpJnOg>?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV3NkSxOUc,OjR3NU[0NVU9N2F-
Caco2	M3G5VGZ2dmO2aX;uJGF{e2G7	NWLLWI5COy9zMD:zNEDPxE1?	M13s[\|E3KGh?	NW[xNHN4TE2VTx?=	MV3pcoNz\WG\|ZYOgeIhmKG2UTlGgcIV3\Wy\|IH;mxsBCU1JzQ{GsJG5SVzFuIFjPMVEtKE2UUEKsxsBidmSPUmCzxsBld3OnLXTldIVv\GWwdHz5	M4G4O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUW2OFE2Lz5{NEW1OlQyPTxxYU6=
Caco2	M4PIcmZ2dmO2aX;uJGF{e2G7	MofiN\|DDqM7:TR?=	NVrJSIlpOjRiaB?=	NVzqcYdpTE2VTx?=	NGPzWpZqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGhQNTFuIFHLVlFENCCjbnSgUnFQOQ>?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV3NkSxOUc,OjR3NU[0NVU9N2F-
SW620	M1rMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTMNVAuPzBibXevUC=>	NH3TRpAzPC92OD:3NkBp		Mm\pbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NEHEdXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[0OlMxPSd-MkS2OFY{ODV:L3G+
SW480	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWjSN5B6PDhiaNMg		MoHSTWM2OD1{MD64JJVoN22O	NFnXR2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyNFY4PSd-MkS3NlA3PzV:L3G+
HCT116	MoPmSpVv[3Srb36gRZN{[Xl?	NEjZcGwzNzViwsXN	NH\iZWgzPC92ODDo		NUDLNW15e3WycILld5NmeyC\|dYL2bZZqdiCvUl7BJIV5eHKnc4Ppc44>	NYTTNW14RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlE1OTFpPkK0O\|YyPDFzPD;hQi=>
HT-29	M1\MSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXpc\|EyyqEQvF2=	NU\aboMzOC15MjDo		M3\BOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz	NFzM[JA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O\|Q2OSd-MkS5PVc1PTF:L3G+
SW480	MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVH2V5d[OcLizszN	NEDMRYQxNTd{IHi=		NFXHd3pqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>?	NEKxUXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O\|Q2OSd-MkS5PVc1PTF:L3G+
HUVEC	MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fPV2lEPTB;MUGuN\|DDqMLzwrCxMlAzKM7:TR?=	NVPnR2M5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N\|A4PDR6PD;hQi=>
HEK293	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTI[FJKSzVyPUiuPFLDqMLzwrC1MlU6KM7:TR?=	M{TmWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO\|Q1QDxxYU6=
HT-29	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkKxTWM2OD53MDFOwG0>	NUn5UY11RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N\|A4PDR6PD;hQi=>
HCT-116	NFKyNWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIC2NmpKSzVyPU[uNlTDqMLzwrCyMlk4KM7:TR?=	NVO5SXFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N\|A4PDR6PD;hQi=>
MCF-7	NWPK[mx3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTF2LkK0xsDDucLiMT64NkDPxE1?	M3XBOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO\|Q1QDxxYU6=
HepG2	M3e5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDPTWM2OD1zND6yOOKhyrIEoEGuPFIh\|ryP	NWn3eFk2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N\|A4PDR6PD;hQi=>
A549	NFPWfW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYm4[XF6UUN3ME21NU4xQMLiwsJCpFExNjl4IN88US=>	NIHFdGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwO\|Q1QCd-MkWzNFc1PDh:L3G+
SGC7901	NHfrN\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{exeGlEPTB;MkGuO\|PDqMLzwrCzMlA5KM7:TR?=	MoPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
COC1	M2fHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zjcmlEPTB;NE[uNlDDqMLzwrCzMlE1KM7:TR?=	NY\zd3lbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N\|A4PDR6PD;hQi=>
HCT116	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIfaSYs4OiCqwrC=		MkjYTWM2OD14LkKzxtExNjd3INM1[{9uVA>?	MlXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|NkC2N\|EoRjJ3M{[wOlMyRC:jPh?=
SW480	M{H6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVe3NkBpyqB?		NEfFeIVKSzVyPUGwMlfDuTJwMk[gxtVoN22O	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4ME[zNUc,OjV\|NkC2N\|E9N2F-
MIAPaCa-2	Mkj3SpVv[3Srb36gRZN{[Xl?	MmrpNlXjiIoEtV2=	NFzRXWgzPC92ODDo		NUD1WI9scW6mdXPld{BkdGWjdnHn[UBw\iCSQWLQMEBk[XOyYYPlMVktKGOjc4Dhd4UuQCCjbnSgZ4F{eGG\|ZT2zxsA>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
Panc-1	NFz4RVdHfW6ldHnvckBCe3OjeR?=	NIW1R3ozPeLCidM1US=>	NUW4VIhyOjRxNEigbC=>		MmXSbY5lfWOnczDjcIVifmGpZTDv[kBRSVKSLDDjZZNx[XOnLUmsJINie3Cjc3WtPEBidmRiY3HzdIF{\S1\|wrC=	M1nTZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NES0PVE1Lz5{NUS0OFkyPDxxYU6=
MIAPaCa-2	MVTBdI9xfG:\|aYOgRZN{[Xl?	MlvDNlXjiIoEtV2=	NIr5e5MzPCCq		MXPpcoR2[2W\|IHHwc5B1d3OrczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC	NFrteGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS0OFkyPCd-MkW0OFQ6OTR:L3G+
Panc-1	MYDBdI9xfG:\|aYOgRZN{[Xl?	MoPQNlXjiIoEtV2=	NHfwd\|EzPCCq		NWK4SFVXcW6mdXPld{BieG:ydH;zbZMhcW5iYTDzfY5memerc4TpZ{Bu[W6wZYKgZ49u[mmwZXSge4l1cCCZQR?=	MnzNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
HPDE	M4XBZ2NmdGxiVnnhZoltcXS7IFHzd4F6	Mo[2NlUwPTBizszN	NIDMXoEzPC92ODDo		NXO1cIlYcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m\|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD	M{LsO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NES0PVE1Lz5{NUS0OFkyPDxxYU6=
SW1990	NIjvT21E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M4mxOFI2NzVyIN88US=>	NGDLVXozPC92ODDo		MmmzbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC	MmDGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
MIAPaCa-2	M1\6fGNmdGxiVnnhZoltcXS7IFHzd4F6	MXqyOU82OCEQvF2=	NHHxcoUzPC92ODDo		M37mPYlvcGmkaYTzJJBzd2yrZnXyZZRqd25ib3[gVGMh[2WubIOgbY4h[SC\|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>?	NV3MS45URGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OFQ6OTRpPkK1OFQ1QTF2PD;hQi=>
Panc-1	MXPD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NFXu[HIzPS93MDFOwG0>	M4S1ZlI1NzR6IHi=		NY\RUmg5cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m\|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD	NHjMSnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS0OFkyPCd-MkW0OFQ6OTR:L3G+
A549/CDDP	NHe3N2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fOXWlEPTB;MUiuOkDDuSBzLkKg{txO	NED1[VE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVI1Oyd-MkW2NlUzPDN:L3G+
A549	NFroTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvMUGhKSzVyPUWuPEDDuSByLk[g{txO	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NUK0N{c,OjV4MkWyOFM9N2F-
SW480	M3GxU2Z2dmO2aX;uJGF{e2G7	MWOxNQKBkcL3Zz;tcC=>	NVPmVJNyOjUkgJno		MW\lcohidmOnczDj[YxtfWyjcjDheZRweGijZ3njJIZtfXh?	M2PSOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5OFIxLz5{NUe0PVQzODxxYU6=
SW620	MUDGeY5kfGmxbjDBd5NigQ>?	M1r1WVEx6oDLwsXnM41t	MkTCNlTjiImq		NX;FXHpE\W6qYX7j[ZMh[2WubIXsZZIh[XW2b4DoZYdq[yCobIX4	M360VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5OFIxLz5{NUe0PVQzODxxYU6=
SW480	MYfGeY5kfGmxbjDBd5NigQ>?	M4PXPVEx6oDLwsXnM41t	NGrqbJUzPOLCiXi=		NEfNUYlqdmO{ZXHz[ZMhVEN\|LVnJJIFk[3WvdXzheIlwdiCjbnSg[IVkemWjc3XzJHA3OiCneIDy[ZN{cW:w	MmXuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEm0NlAoRjJ3N{S5OFIxRC:jPh?=
SW620	M3fTbGZ2dmO2aX;uJGF{e2G7	M2H3TlEx6oDLwsXnM41t	MoPINlTjiImq		NVvudHlXcW6lcnXhd4V{KEyFMz3JTUBi[2O3bYXsZZRqd25iYX7kJIRm[3KnYYPld{BRPjJiZYjwdoV{e2mxbh?=	Ml\PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEm0NlAoRjJ3N{S5OFIxRC:jPh?=
HT-29	M1rud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;FTWM2OD13LkKyJO69VQ>?	M1LpWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xOFc6Lz5{NUe2NVQ4QTxxYU6=
SNU-175	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjNUo42UUN3ME2xMlUyKM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUS3PUc,OjV5NkG0O\|k9N2F-
COLO-320DM	M1rsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDFRVFzUUN3ME21MlM5KM7:TR?=	M4rjZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xOFc6Lz5{NUe2NVQ4QTxxYU6=
DLD-1	M{H6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zGUWlEPTB;OD62OUDPxE1?	NEPsVo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVQ4QSd-MkW3OlE1Pzl:L3G+
DiFi	MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTFyLkm1JO69VQ>?	M4fBUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xOFc6Lz5{NUe2NVQ4QTxxYU6=
HCT-15	M{\yUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\ufmlEPTB;OD62OEDPxE1?	MnmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkG0O\|koRjJ3N{[xOFc6RC:jPh?=
SCM-1	NGnPSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfhb5JKSzVyPUG3MlUh\|ryP	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd6OUC1O{c,OjV5OEmwOVc9N2F-
TMK-1	MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LC[WlEPTB;MkKuOkDPxE1?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd6OUC1O{c,OjV5OEmwOVc9N2F-
MKN-45	MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrQTWM2OD1zND6wJO69VQ>?	MkDsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEmwOVcoRjJ3N{i5NFU4RC:jPh?=
AGS	NGLvcXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\RTWM2OD1zMD62JO69VQ>?	NIrVV2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe4PVA2Pyd-MkW3PFkxPTd:L3G+
S3	NFTYOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHm2e\|hKSzVyPUWzMlUhyrFiMT61JO69VQ>?	NYHTNnZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFExODdpPkK1PFAyODB5PD;hQi=>
SiHa	NV;veXZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1v2TmlEPTB;MD64JOKyKDBwMTFOwG0>	NGfMfXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiwNVAxPyd-MkW4NFExODd:L3G+
HT-29	MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4T1dmlEPTB;M{WuOkDPxE1?	NFrOWHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwN\|A5PSd-Mk[wNFMxQDV:L3G+
DLD-1	NHzTUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTN{LkKg{txO	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByM{C4OUc,OjZyMEOwPFU9N2F-
HT29	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmezTWM2OD14MzFOwG0hyrFiMUi=	MnzRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMESwPFQoRjJ4MEC0NFg1RC:jPh?=
MC38	NXzoT3hYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTJ\|IN88UUDDuSB{	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByNEC4OEc,OjZyMESwPFQ9N2F-
SW620	NIHvUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHsfodzUUN3ME2zMlY5KM7:TR?=	Mn[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
SW480	NVjR[JNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTJwOE[g{txO	MlHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
RKO	M3XmZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnF[\|NKSzVyPUGuNlMh\|ryP	M1q3RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN\|A5PTxxYU6=
LoVo	MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HhS2lEPTB;MT6yJO69VQ>?	NFKxeHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN\|A5PSd-Mk[wNlMxQDV:L3G+
KM12	M2nsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLQVHdKSzVyPUSuN\|ch\|ryP	M3rTRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN\|A5PTxxYU6=
HCT116p53-	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTFwMEig{txO	NWHGN5JnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlMxQDVpPkK2NFI{ODh3PD;hQi=>
HCT116	NULa[pY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTFwMESg{txO	NXj1c2RsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlMxQDVpPkK2NFI{ODh3PD;hQi=>
HCT15	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3ztR2lEPTB;MT60N{DPxE1?	NEDMToQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN\|A5PSd-Mk[wNlMxQDV:L3G+
HT29	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXwTWM2OD1{Lk[5JO69VQ>?	NVG4Um1TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlMxQDVpPkK2NFI{ODh3PD;hQi=>
DLD1	MlXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nlVmlEPTB;Mj6wNUDPxE1?	NELORnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN\|A5PSd-Mk[wNlMxQDV:L3G+
Colo205	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLoTWM2OD1\|LkOzJO69VQ>?	MmW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
BE	NXzuWI5JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDCTWM2OD1\|LkOzJO69VQ>?	M32zVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN\|A5PTxxYU6=
CT26	NGj0[mZE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M3fo[\|QhdU1?	MkfsOFghcMLi		NW\RN\|g6\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJRwKDV\|LkKl	M2fybVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO3NFEzLz5{NkGzO\|AyOjxxYU6=
CT26	MmPSSpVv[3Srb36gRZN{[Xl?	NVLkfmFYPCCvTR?=	MYO0PEBpyqB?		M4C1Zolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdHNib3[gZZV1d3CqYXf5MZJmdGG2ZXSgdJJwfGWrboOsJJN2[2hiYYOgUGM{NUmLLDDC[YNtcW5zIHHu[EBCXEd3	Mn7DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{ewNVIoRjJ4MUO3NFEzRC:jPh?=
CT26	NXrYOlQ6TnWwY4Tpc44hSXO\|YYm=	M37KNFQhdU1?	M{DOXVQ5KGkEoB?=		NIrNepJqdmS3Y3XzJIF2fG:yaHHnfS=>	NYr6N3VIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|cxOTJpPkK2NVM4ODF{PD;hQi=>
SK-OV-3	MknsSpVv[3Srb36gRZN{[Xl?	MoXZOVAh\|ryPwrC=	MWS0PEBpyqB?		NF\0[Jdxem:vb4Tld{B{\W6\|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=>	NEfodXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN\|g3PzF:L3G+
OVCAR-5	M3rZPGZ2dmO2aX;uJGF{e2G7	MW[yNEDPxE4EoB?=	NF\MOXgzPGh?		NGP1VnFxem:vb4Tld{B{\W6\|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=>	NU\seYR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|g3PzFpPkK2NVM5PjdzPD;hQi=>
PA-1	MlLqSpVv[3Srb36gRZN{[Xl?	NX32XXZvOTBizszNxsA>	Ml\pNlRp		NVrPeXMyeHKxbX;0[ZMhe2Wwc3n0bZZqfHlib3[gc5ZiemmjbjDjZZJkcW6xbXGgeI8hVktiY3XscE1u\WSrYYTl[EBkgXSxbInzbZM>	NXrtfmdVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|g3PzFpPkK2NVM5PjdzPD;hQi=>
SK-OV-3	M1\KTGZ2dmO2aX;uJGF{e2G7	MYK1NEDPxE1?	NH\xVW06PiCq		Ml:yeZAuemWpdXzheIV{KHSqZTDzeJJme3NibHnnZY5leyCob4KgUmsh[2WubD3hZ5RqfmG2aX7nJJJm[2WydH;yd{BidmRiVGLBTWwhemWlZYD0c5J{	NHjhcXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN\|g3PzF:L3G+
OVCAR-5	NIjFPHhHfW6ldHnvckBCe3OjeR?=	M4nSO\|MxKM7:TR?=	NYPr[40{PDiq		NWnNXXA3fXBvcnXneYxifGW\|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K\|	NHvYbXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN\|g3PzF:L3G+
PA-1	NGrFcZJHfW6ldHnvckBCe3OjeR?=	MYKxNEDPxE4EoB?=	MXK0PIg>		MYr1dE1z\We3bHH0[ZMhfGinIIP0doV{eyCuaXfhcoR{KG[xcjDOT{Bk\WyuLXHjeIl3[XSrbnegdoVk\XC2b4LzJIFv\CCWUlHJUEBz\WOncITvdpM>	NU\sdnFDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|g3PzFpPkK2NVM5PjdzPD;hQi=>
SK-OV-3	MnzlSpVv[3Srb36gRZN{[Xl?	NH7F[\|Q2OCEQvF2=	M{DpWFk3KGh?		NEXhSGN1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM>	MnrEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O\|EoRjJ4MUO4OlcyRC:jPh?=
OVCAR-5	M2jiPGZ2dmO2aX;uJGF{e2G7	NYL5[ldNOzBizszN	NW\YN5dWPDiq		NH3l[3Z1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM>	NX\1emtyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|g3PzFpPkK2NVM5PjdzPD;hQi=>
PA-1	MlLsSpVv[3Srb36gRZN{[Xl?	MX[xNEDPxE4EoB?=	NIP5O2szPGh?		M3XZc5RzcWepZYLld{B1cGVicILv[JVkfGmxbjDv[kB1gXCnIFmgTWZPeyCjbnSgZ4hmdW:taX7ldy=>	NWmwNmI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|g3PzFpPkK2NVM5PjdzPD;hQi=>
SK-OV-3	MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MoLYNE0yODBizszN	M3TNS\|I1NzR6L{eyJIg>		NVjtT5NOcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|OE[3NUc,OjZzM{i2O\|E9N2F-
OVCAR-5	NGX4eGJE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NYr3bpRWOC14MDFOwG0>	MoT0NlQwPDhxN{KgbC=>		NGL1cY5qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MkDNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O\|EoRjJ4MUO4OlcyRC:jPh?=
PA-1	M1flUGNmdGxiVnnhZoltcXS7IFHzd4F6	MXKwMVIxKM7:TR?=	Ml7DNlQwPDhiaB?=		M1TwWIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	NVSzVGltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|g3PzFpPkK2NVM5PjdzPD;hQi=>
HCT116	NUHINHB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfaTWM2OD1yLkSxxsDDucLiMD6wNkDPxE1?	NX3LS2hPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xOFg2QTZpPkK2NVQ5PTl4PD;hQi=>
HT29	Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2L5SWlEPTB;MD64POKhyrIEoECuNkDPxE1?	NUXl[4lCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xOFg2QTZpPkK2NVQ5PTl4PD;hQi=>
SNU-387	M17nW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnSV29wUUN3ME2yOeKhyrIEoEKuO{DPxE1?	NVjJRVY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xOlA1OjlpPkK2NVYxPDJ7PD;hQi=>
SNU-475	NXKzNmxQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|Ux97zgM{Cg{txO	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF4MESyPUc,OjZzNkC0Nlk9N2F-
Hep-G2	MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVu4eXBbUUN3ME2xN{4yyqEEsdMgNU43KM7:TR?=	NXnHd2liRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xOlA1OjlpPkK2NVYxPDJ7PD;hQi=>
SNU-398	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;zWWlEPTB;Nj61xsDDucLiMT6xJO69VQ>?	M2DVfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MU[wOFI6Lz5{NkG2NFQzQTxxYU6=
LoVo	NGLvXHBHfW6ldHnvckBCe3OjeR?=	Ml3UNU82KM7:TR?=	MUSyOE81QCCq		M4PIUIlv\HWlZYOgeJJidnOlcnnweIlwdmGuIILldJJme3Orb36gc4YhTFWWLV6=	NYHjV4ttRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNFg2OjNpPkK2NlA5PTJ\|PD;hQi=>
HCT116 p53+/+	MkHZSpVv[3Srb36gRZN{[Xl?	NHfEcoIyNzVizszN	NInIZ5YzPC92ODDo		NHP2UGVqdmS3Y3XzJJRz[W6\|Y4LpdJRqd26jbDDy[ZBz\XO\|aX;uJI9nKESXVD3O	M2LzOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkC4OVI{Lz5{NkKwPFUzOzxxYU6=
MDA-MB-231	M2nu[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPHclFMUUN3ME2yN{4yKMLzIECuNUDPxE1?	M1mzelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkGxOVkyLz5{NkKxNVU6OTxxYU6=
MCF-7	NXLmO4ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17WRWlEPTB;MUWuOEDDuSByLkOg{txO	M4OxR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkGxOVkyLz5{NkKxNVU6OTxxYU6=
SK-BR-3	NUP0[5FkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTNzLkCgxtEhOC5zIN88US=>	MoXCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MUG1PVEoRjJ4MkGxOVkyRC:jPh?=
LoVo	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1nGR\|Q5KGkEoB?=		NXG2O\|BnUUN3ME25OE45OyEQvF2=	M4jXT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mk[5O\|U6Lz5{NkK2PVc2QTxxYU6=
HCT116	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV[0PEBpyqB?		M2XSdmlEPTB;MUGuPFYh\|ryP	NVzoNGNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOlk4PTlpPkK2NlY6PzV7PD;hQi=>
SW480	NY\5XnpST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHjTSZc1QCCqwrC=		NFz6NGxKSzVyPUGuPFch\|ryP	NV3zSFVjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOlk4PTlpPkK2NlY6PzV7PD;hQi=>
CaES-17	Mn\1R5l1d3SxeHnjbZR6KEG\|c3H5	MWiw5qCUOTZywrFOwG0>	MlvOOFjDqGh?		MmS4TWM2OD13LkZCpOKyyqByLkKg{txO	M172Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEe0Olk{Lz5{NkS3OFY6OzxxYU6=
HKESC-2	MYHDfZRwfG:6aXPpeJkhSXO\|YYm=	M1XwPFDjiJNzNkFCpO69VQ>?	MUO0POKhcA>?		M3fp[2lEPTB;NT64xsDDucLiMD61JO69VQ>?	M1LJT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEe0Olk{Lz5{NkS3OFY6OzxxYU6=

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	VEGFR-1 / NRP-1 ; p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416) ; p-Src(Y418) / p-FAK(Y861)	18790786 19383922
Immunofluorescence	E-cadherin / Vimentin ; ATXN2L / G3BP1	30787271
Growth inhibition assay	Cell viability	28339092

In vivo

A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. ^[6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C₂₆ colon carcinoma xenografts. ^[7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. ^[8]

Protocol (from reference)

Cell Research:

^[4]

Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
Concentrations: ~100 μM
Incubation Time: 48 hours
Method:
The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO₂ and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 10³ cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control
(Only for Reference)

Animal Research:

^[6]

Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
Dosages: 10 mg/kg
Administration: A weekly i.p. injection
(Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	Water	3 mg/mL warmed (7.55 mM)
	DMF	Insoluble
	Ethanol	''0.01 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	397.29
Formula	C₈H₁₄N₂O₄Pt
CAS No.	61825-94-3
Storage	2 years 4°C(in the dark) powder
Smiles	C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]

Download Oxaliplatin (NSC 266046) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05025826	Not yet recruiting	Other: Phycocare\|Other: Placebo	Metastatic Gastric Cancer	Nantes University Hospital\|Algosource	November 5 2021	Not Applicable
NCT05031975	Not yet recruiting	Drug: Irinotecan\|Drug: Temozolomide	Colorectal Cancer	Fondazione IRCCS Istituto Nazionale dei Tumori Milano	November 1 2021	Phase 2
NCT05068531	Not yet recruiting	--	Colorectal Cancer Metastatic	Centre hospitalier de l''Université de Montréal (CHUM)\|Exactis Innovation\|Chaire Roger Des Groseillers d''oncologie chirurgicale HBP de l''Université de Montréal\|Canexia Health	October 2021	--
NCT04158349	Terminated	Drug: Oxaliplatin\|Drug: mFOLFIRI	Colorectal Cancer\|Appendiceal Cancer\|Peritoneal Carcinoma	University of Utah	March 22 2021	Phase 1
NCT04944550	Recruiting	--	Upper Urinary Tract Urothelial Carcinoma\|Nephroureterectomy\|Tumor\|Xenograft Model	Centre Hospitalier Universitaire de Nīmes\|INSERM U1194 Institut de Recherche en Cancérologie de Montpellier Campus Val d''Aurelle 34298 Montpellier cedex 5	March 1 2021	--

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
Is it ok to dissolve Oxaliplatin in DMSO?

Answer:
Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):